Additional file 3 of Neuropilin 1 and Neuropilin 2 gene invalidation or pharmacological inhibition reveals their relevance for the treatment of metastatic renal cell carcinoma
posted on 2021-01-19, 04:39authored byAurore Dumond, Etienne Brachet, Jérôme Durivault, Valérie Vial, Anna K. Puszko, Yves Lepelletier, Christopher Montemagno, Marina Pagnuzzi-Boncompagni, Olivier Hermine, Christiane Garbay, Nathalie Lagarde, Matthieu Montes, Luc Demange, Renaud Grépin, Gilles Pagès
Additional file 3: Fig. S2. Effects of NRP1 or NRP2 gene invalidation in RENCA cells. (A) NRP1 and NRP2 protein levels were evaluated by flow cytometry in control (RENCA), in #NRP1 4.1.7 and #NRP2 5.1.8 clones. (B) Effects of NRPs KO on RENCA cell metabolic activity measured by MTT assays. (C) Effects of NRPs KO in RENCA cells on the VEGFA and VEGFC protein levels measured by ELISA. *p < 0.05; **p < 0.01; *** p < 0.001.
Funding
Helsinn Centre Scientifique de Monaco Fondation de France Institut National Du Cancer Agence Nationale Recherche (ANR) Ligue Contre le Cancer Conseil général des Alpes Maritimes Association Cordons de Vie Fondation François Xavier Mora Fondation Flavien